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DObjectives: Pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary
hypertension. Although several reports demonstrated excellent medium-term survival after pulmonary endarter-
ectomy, long-term outcomes remain unclear. We reviewed long-term outcomes and determined risk factors for
early and late adverse events.
Methods: Seventy-seven patients were studied. Mean pulmonary arterial pressure was 47 10 mmHg and pul-
monary vascular resistance was 868  319 dyne $ s $ cm5. Disease was classified as chronic thromboembolic
pulmonary hypertension type 1 (n ¼ 61), type 2 (n ¼ 12), or type 3 (n ¼ 4). Median and maximum follow-up
periods were 5.6 and 20 years, respectively.
Results: There were 11 in-hospital deaths. Nonsurvivors had significantly higher mean pulmonary arterial pres-
sure and pulmonary vascular resistance than did survivors (54 10 vs 46 10 mm Hg; P¼ .02; 1124 303 vs
824  303 dyne $ s $ cm5; P<.01). In multivariate analysis, preoperative pulmonary vascular resistance was
associated with in-hospital death (odds ratio, 1.003; 95% confidence interval, 1.001–1.005; P<.01). During
follow-up, there were 10 all-cause deaths, including 5 related to chronic thromboembolic pulmonary hyperten-
sion. Freedom from adverse events, including disease-specific death or New York Heart Association functional
class III, was 70% at 10 years. In the Cox proportional hazard model, postoperative mean pulmonary arterial
pressure was associated with adverse events (hazard ratio, 1.12; 95% confidence interval, 1.03–1.21;
P< .01). Receiver operating characteristic curve analysis showed mean pulmonary arterial pressure of 34
mm Hg as cutoff for adverse events.
Conclusions: Pulmonary endarterectomy had sustained favorable effects on long-term survival. High pulmo-
nary vascular resistance was associated with in-hospital death, and postoperative mean pulmonary arterial pres-
sure was an independent predictor of adverse events. (J Thorac Cardiovasc Surg 2012;144:321-6)Chronic thromboembolic pulmonary hypertension
(CTEPH) is a life-threatening disease caused by unresolved,
organized thrombi obstructing the pulmonary arteries.1,2
Progressive pulmonary hypertension severely com-
promises both clinical functional status and exercise
capacity as a result of ventilation–perfusion mismatch and
decreased cardiac output. In patients who do not undergo
operation, the prognosis is disappointing and is
determined by the severity of the pulmonary hypertension:
if mean pulmonary arterial pressure (mPAP) exceeds 30
mm Hg, the 5-year survival is less than 30%, and if it
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The Journal of Thoracic and CaPulmonary endarterectomy (PEA), which has been estab-
lished as a standard surgical treatment for CTEPH, is per-
formed worldwide, mostly at centers with experience.1,4
PEA offers immediate and substantial decreases in both
mPAP and pulmonary vascular resistance (PVR) and an
increase in the cardiac index.4,5 Medium-term follow-up re-
sults for PEA reveal favorable effects on survival and clin-
ical functional status6-10; however, the long-term outcomes
remain unclear because of the limited available data. We be-
gan our PEA program in 1986 and have thus been perform-
ing the operation now for more than 20 years. Early on in
our series, we performed PEA through a lateral thoracot-
omy; however, we have performed PEA through median
sternotomy with intermittent deep hypothermic circulatory
arrest according to the San Diego group procedure since
1990.4,11,12 Here we review the long-term follow-up out-
comes of a consecutive series of patients who underwent
PEA through median sternotomy, and we seek to determine
the factors influencing both early and late survival and func-
tional status.
MATERIALS AND METHODS
Between 1990 and 2010, a total of 77 patients underwent PEA at Chiba
University Hospital and affiliated hospitals. We retrospectively reviewedrdiovascular Surgery c Volume 144, Number 2 321
Abbreviations and Acronyms
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
mPAP ¼ mean pulmonary arterial pressure
NYHA ¼ New York Heart Association
PEA ¼ pulmonary endarterectomy
PVR ¼ pulmonary vascular resistance
Acquired Cardiovascular Disease Ishida et al
A
C
Dthis cohort of patients. All 77 patients in our cohort underwent preoperative
pulmonary angiography, right heart catheterization, and computed tomo-
graphic scan. Surgical indications were decided as follows: PVR greater
than 300 dyne $ s $ cm5, mPAP greater than 30 mm Hg, New York Heart
Association (NYHA) functional class greater than II, and absence of signif-
icant comorbidities. Postoperative pulmonary hemodynamics were evalu-
ated by right heart catheterization 1 month after PEA in 61 of the 66
PEA survivors. Perioperative data were collected from hospital records.
Follow-up data, which were obtained by calling the patients or their pri-
mary physicians, were available for 74 patients (96% complete). The me-
dian and maximum follow-up periods were 5.6 years and 20 years,
respectively.
Baseline patient characteristics are shown in Table 1. Fifty-five patients
(56%) were female, and thus the gender distribution was female dominant.
Twenty-four patients (31%) had a coagulation abnormality (antithrombin
III deficiency, 5 patients; protein C or S deficiency, 5 patients; antiphospho-
lipid syndrome, 9 patients), and 37 patients (48%) had a deep vein throm-
bosis. Most of the patients (79%) were in NYHA functional class III or IV,
and all patients required home oxygen therapy. ThemPAPwas 47 10mm
Hg, with 42% of the patients having mPAP values greater than 50 mm Hg.
PVR was 868 319 dyne $ s $ cm5, with 30% of the patients having PVR
values greater than 1000 dyne $ s $ cm5.
On the basis of the location and morphology of the thromboembolic and
vascular wall disease found at the time of surgery, the diseasewas classified
as follows: type 1 (n ¼ 61) consisted of fresh (acute) thrombus in the main
lobar pulmonary arteries; type 2 (n ¼ 12) consisted of intimal thickening
and fibrosis with or without organized thrombus proximal to the segmental
arteries; type 3 (n¼ 4) consisted of fibrosis, intimal webbing, and thicken-
ing with or without an organized thrombus within distal segmental arteries
alone; and type 4 (n ¼ 0) consisted of microscopic distal arteriolar vascul-
opathy without visible thromboembolic disease.13
PEA was performed through a median sternotomy with intermittent
deep hypothermic circulatory arrest according to the procedure of Univer-
sity of California, San Diego group.4,11,12 An inferior vena cava filter was
put in place in 65 patients (84%). All PEA survivors received permanent
anticoagulation therapy (Coumadin). Pulmonary vasodilator therapy
(bosentan or sildenafil citrate [INN sildenafil]) was not routinely used,
except for patients in NYHA functional class III.
Statistics
Results are expressed as mean SD. All analyses were performed with
SPSS 18 software (IBMCorporation, Armonk, NY). TheWilcoxon signed-
rank test was used for the comparison of preoperative and postoperative
pulmonary hemodynamic data. Pulmonary hemodynamic data obtained
by right heart catheterization 1 month after PEAwere used for the calcula-
tion of postoperative mPAP or PVR, except in the case of patients who did
not undergo postoperative right heart catheterization; for these patients, the
data obtained before removal of the thermodilution catheter were used. Pre-
dictors of in-hospital mortality were analyzed by univariate analysis and
multivariate stepwise logistic regression analysis. The univariate analysis
was performed for continuous variables with a t test or a Mann-Whitney322 The Journal of Thoracic and Cardiovascular Surgtest and for categoric variables with the c2 test or the Fisher’s Exact test.
We calculated the incidence rates for all-cause mortality, disease-specific
mortality, and adverse events, including disease-specific mortality and im-
paired functional status in NYHA functional class III, and we used the
Kaplan-Meier method to estimate survivals. Univariate and multivariate
stepwise analyses with the Cox proportional hazard model were performed
to identify the risk factors for disease-specific death and adverse events.
The optimal PVR cutoff point for in-hospital death and the optimal
mPAP cutoff value for adverse events were determined with the aid of a re-
ceiver operating characteristic curve. Results are expressed as hazard ratios
with 95% confidence intervals.RESULTS
Early Results
There were 11 in-hospital deaths among the cohort stud-
ied (14%). The causes of death were as follows: right heart
failure (n ¼ 6), pulmonary hemorrhage (n ¼ 2), cardiac
tamponade (n ¼ 2), and reperfusion lung edema (n ¼ 1).
With the exception of the 2 patients who died of cardiac
tamponade, the other 9 patients had persistent pulmonary
hypertension develop, and there were 5 patients who could
not be weaned from cardiopulmonary bypass. Among the
66 PEA survivors, mPAP and PVR decreased (from 47 
10 mm Hg to 25  10 mm Hg, P< .0001; from 868 
319 dyne $ s $ cm5 to 313  206 dyne $ s $ cm5,
P < .0001; respectively), and cardiac index increased
(from 2.5  0.7 L/[min $ m2] to 3.1  0.6 L/[min $ m2];
P<.0001). Comparisons between survivors and nonsurvi-
vors in terms of preoperative data are shown in Table 2.
In the multivariate analysis, only preoperative PVR (odds
ratio, 1.003; 95% confidence interval, 1.001–1.005;
P<.01) was an independent predictor of in-hospital death.
To determine the cutoff point for the influence of preopera-
tive PVR on in-hospital death, we performed receiver oper-
ating characteristic curve analysis. This revealed
a preoperative PVR of 1052 dyne $ s $ cm5 as the cutoff
value for in-hospital death (area under the curve, 0.76; sen-
sitivity, 0.64; specificity, 0.83).Late Results
During the follow-up period, there were 10 all-cause
deaths. Four deaths of right heart failure and 1 sudden car-
diac death were regarded as being related to CTEPH. These
patients exhibited NYHA functional class III symptoms as
a result of persistence or worsening of pulmonary hyperten-
sion: 3 patients had persistent pulmonary hypertension with
less than 10% decrease in PVR, and 2 patients had worsen-
ing of pulmonary hypertension despite early postoperative
decrease in PVR (from 618 dyne $ s $ cm5 to 386 dyne $
s $ cm5 and from 1288 dyne $ s $ cm5 to 507 dyne $ s $
cm5). Other causes of death included suffocation hematem-
esis, interstitial pneumonia, brain hemorrhage, and stroke.
Among the operative survivors, clinical functional status
improved markedly relative to the preoperative status. At
the most recent follow-up at a mean of 6.5 years, 56 patientsery c August 2012
TABLE 1. Baseline patient characteristics
Variable Preoperative
Male (no.) 34 (44%)
Age (y, mean  SD) 55  11
Coagulation abnormality (no.) 24 (31%)
Deep vein thrombosis (no.) 37 (48%)
Insertion of inferior vena cava filter (no.) 65 (84%)
Duration of illness (mo, mean  SD) 49.6  40.4
New York Heart Association functional class (no.)
I 0
II 16 (21%)
III 54 (70%)
IV 7 (9%)
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D(92%) were in NYHA functional class I or II, and 35 pa-
tients (63%) had been weaned from home oxygen therapy.
Among 5 patients in NYHA functional class III, 4 patients
had worsening of pulmonary hypertension at follow-up.
Their PVR decreased from 795  245 dyne $ s $ cm5 to
398  146 dyne $ s $ cm5 early after surgery, but it rose
again to 738  214 dyne $ s $ cm5 at follow-up.
Figure 1 shows freedoms from all-cause death, disease-
specific death, and adverse events (including disease-
specific death and impaired functional status, NYHA
functional class III). The values for freedom from
disease-specific death at 5 and 10 years were 84% and
82%, respectively, whereas those for freedom from ad-
verse events were 78% and 70%.
We next sought to determine risk factors for late adverse
events. In the individual variable model, age and postoper-
ative mPAP and PVR were associated with adverse events;
however, only postoperative mPAP was found to be signif-
icant in the multivariable analysis (hazard ratio, 1.12; 95%
confidence interval, 1.03–1.21; P<.01). Receiver operat-
ing characteristic curve analysis revealed a postoperative
mPAP of 34 mm Hg as the cutoff value for adverse events
(area under the curve, 0.90; sensitivity, 0.80; specificity,
0.91).
Finally, the postoperative mPAP cutoff value was used to
divide patients into 2 groups. There were no intergroupTABLE 2. Risk factors for hospital mortality
Variable Survivors (
Male (no.) 27 (41%
Duration of illness (mo, mean  SD) 47 
Mean pulmonary arterial pressure (mm Hg, mean  SD) 46 
Pulmonary vascular resistance (dyne $ s $ cm5, mean  SD) 825 
Cardiac index (L/[min $ m2], mean  SD) 2.5 
Chronic thromboembolic pulmonary hypertension type (no.)
1 52 (87%
2 12 (100
3 2 (50%
*Versus chronic thromboembolic pulmonary hypertension types 1 and 2.
The Journal of Thoracic and Cadifferences in any preoperative variables, although patients
with a postoperative mPAP of at least 34 mmHg had a trend
toward higher preoperative mPAP values than did those
with a postoperative mPAP lower than 34 mm Hg (50 
10 mm Hg vs 45  10 mm Hg; P ¼ .10). Comparison of
freedom rates from late adverse events between the groups
(Figure 2) revealed that patients with postoperative mPAP
values lower than 34 mm Hg had good late outcomes. In
that group, 10-year freedoms from disease-specific death
and adverse events were 100% and 98%, respectively. In
contrast, patients with postoperativemPAP values of at least
34 mmHg had significant adverse events after PEA, and 10-
year freedoms from disease-specific death and adverse
events were 80% and 41%, respectively.DISCUSSION
Medical treatment for CTEPH is palliative and unsatis-
factory, but PEA is an effective therapeutic option that re-
sults in immediate and substantial improvements in
pulmonary hemodynamics. This procedure is technically
demanding, however, and requires proper patient selection
and careful postoperative management, resulting in such
relatively high in-hospital mortalities as 4.4% to
16%.1,4,6,10,14,15 Although our overall in-hospital mortality
of 14%may be relatively high, the ratewas reduced to 7.5%
in the last 40 cases with increasing surgical experience and
refinements in operative and postoperative management.
Several risk factors for increased in-hospital mortality
have been identified, including advanced age, severe pul-
monary hemodynamic compromise, CTEPH type 3 or 4,
distinct medical conditions involving other organ
systems, and postoperative PVR greater than 500
dyne $ s $ cm5.1,4,6,13,14,16 In this study, only high
PVR was identified as a preoperative risk factor, with
a PVR cutoff point of 1052 dyne $ s $ cm5 for in-
hospital death. Although other work has shown that post-
operative PVR greater than 500 dyne $ s $ cm5 may be
a significant risk factor for in-hospital death,4 we did not
evaluate postoperative PVR because there were 5 patients
who could not be weaned from cardiopulmonary bypass.n ¼ 66) Nonsurvivors (n ¼ 11)
Univariate
P value
Multivariate
P value
) 7 (63%) .20 —
40 62  39 .27 —
10 54  9 .02 —
303 1124  303 <.01 <.01
0.7 2.1  0.5 .33 —
) 8 (14%)
%) 0 (0%)
) 2 (50%) .10* —
rdiovascular Surgery c Volume 144, Number 2 323
FIGURE 1. Overall Kaplan-Meier survival curves after pulmonary endarterectomy (PEA).A, Freedom from all-cause mortality. B, Freedom from disease-
specific mortality. C, Freedom from disease-specific mortality or New York Heart Association functional class III.
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DA previous study revealed that patients with a PVR
greater than 1100 dyne $ s $ cm5 had 6 times higher op-
erative mortality (37%) than did those with a PVR lower
than 1100 dyne $ s $ cm5.16 Another study by Dartevelle
and colleagues1 showed that the mortality was 4% among
patients with PVR lower than 900 dyne $ s $ cm5; how-
ever, this increased to 10% among those with PVR be-
tween 900 and 1200 dyne $ s $ cm5 and to 20%
among those with higher PVR. High PVR and CTEPH
type 3 have been shown to be associated with persistent
pulmonary hypertension, which is among the majorFIGURE 2. Kaplan-Meier survival curves after pulmonary endarterectomy (P
A, Freedom from disease-specific mortality. B, Freedom from disease-specific
324 The Journal of Thoracic and Cardiovascular Surgcomplications after PEA and the leading cause of in-
hospital death.1,4 In a study by Thistlethwaite and
associates,13 patients with CTEPH type 3 disease had
higher rates of perioperative mortality and morbidity
and smaller decreases in PAP and PVR than did those
with proximal disease (type 1 or 2). Likewise, Freed
and colleagues17 reported less improvement in pulmonary
hemodynamics among patients with CTEPH type 3: 10 of
their 17 patients with type 3 disease had postoperative
persistent pulmonary hypertension, with mPAP values
greater than 30 mm Hg. In the our study, it was notEA) according to postoperative mean pulmonary arterial pressure (mPAP).
mortality or New York Heart Association functional class III.
ery c August 2012
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in-hospital mortality, because only a small number of pa-
tients had CTEPH type 3. Proper patient selection and
careful perioperative management, however, are neces-
sary when treating patients who have a high mPAP as a re-
sult of CTEPH type 3.
In addition to immediate improvements in pulmonary he-
modynamics, PEA reportedly provides an excellent
medium-term survival benefit, with 5-year survivals rang-
ing from 75% to 89%.6-9 In a long-term follow-up of 308
patients who underwent PEA between 1970 and 1994,
a University of California, San Diego, group found that
75% survived beyond 6 years.9 More recently, Corsico
and coworkers8 reported the late results obtained for 157 pa-
tients who underwent PEA between 1994 and 2006. They
showed an 84% survival at 5 years, with a 30-day mortality
of 11.5%. Our study, which reviewed the 20-year follow-up
outcomes of patients who underwent PEA, has confirmed
the persistent beneficial effect of PEA, as indicated by our
late survival data. Indeed, 10-year survival was as high as
82% (Figure 1, B).
Patients with CTEPH are severely clinically compro-
mised as a result of ventilation–perfusion mismatch and de-
creased cardiac output. In previous studies, more than 90%
were in NYHA functional class III or IV, and most required
oxygen therapy.6,8,14 Despite that clinically unpromising
background, PEA provided significant and sustained
improvements in clinical symptoms, with more than 90%
of patients being in NYHA functional class I or II and 2
thirds having been weaned from oxygen therapy at the
latest follow-up.6,8 In addition to prompt pulmonary
hemodynamic improvement, PEA gradually improves gas
exchange through a period of 6 months to 2 years after
a temporal ventilation–perfusion abnormality caused by
restrictive pulmonary functional impairment in response
to surgical trauma, diffusion limitation in response to
pulmonary edema, and a steal of perfusion from high-
resistance nonobstructed segment to low-resistance newly
perfused segements.18,19 In our study, which was
consistent with the previous results, only 63% of patients
could be weaned from oxygen therapy, although 92% of
patients were in NYHA functional class I or II. The
discrepancy between excellent functional status and
frequent oxygen therapy at follow-up can be explained by
the fact that 10 of 21 patients with home oxygen therapy
had a short follow-up period of less than 2 years.
Although a previous follow-up study found that persis-
tent pulmonary hypertension and recurrent pulmonary
embolism were the leading causes of late death,9 the risk
factors for late adverse events after PEA remain to be iden-
tified because the data on long-term survival are relatively
scarce. In one of the few relevant reports, Bonderman and
associates15 showed that distinct medical conditions caus-
ing chronic infection or chronic inflammatory processesThe Journal of Thoracic and Cawere risk factors for persistent pulmonary hypertension af-
ter PEA and were associated with both short- and long-term
adverse outcomes. Freed and colleagues,17 who reviewed
medium-term follow-up results, showed that although per-
sistent pulmonary hypertension with an mPAP value greater
than 30 mm Hg led to impairments in both functional status
and exercise capacity, it had no adverse impact on 5-year
survival. Our long-term follow-up study showed that persis-
tence and worsening of pulmonary hypertension were asso-
ciated with late death or impairment of functional status and
identified postoperative mPAP as a risk factor for late ad-
verse events, whereas the preoperative risk factors for in-
hospital death were not associated with late adverse events.
It has been shown that mPAP determines the prognosis of
patients with medically treated CTEPH.3 Actually, in previ-
ous studies, mPAP values greater than 30 mm Hg adversely
affected survival in patients with medically treated CTEPH,
whereas borderline pulmonary hypertension (20–26 mm
Hg) was not associated with a poor prognosis.3,20 In our
study, a postoperative mPAP value of at least 34 mm Hg
was found to be the cutoff value for late adverse events.
To judge from these results, a high mPAP determines the
prognosis of patients with CTEPH, whether the disease is
treated surgically or medically, and thus a decrease of
mPAP is the most important goal if we hope to achieve
good late survival. In contrast to the poor outcomes
among patients with persistent pulmonary hypertension,
an excellent 10-year event-free survival (98%) was
achieved among patients with resolved pulmonary hyper-
tension (Figure 2). Our result indicates that PEA can be a cu-
rative and definitive surgical treatment and may be
particularly important for patients with CTEPH, who are
generally middle-aged (mean age around 52–57
years).1,4,6,10,14,15
Persistent pulmonary hypertension develops in 10% to
35% of patients who have undergone PEA, despite removal
of sufficient proximal thromboembolic materials.6,10,14,17
Pathologic examination of lung tissue in patients with
CTEPH has shown that small vessel arteriopathy occurs
not only in the area served by open proximal arteries but
also in the area distal to occluded pulmonary
arteries.1,21,22 This small vessel arteriopathy causes
progressive pulmonary hypertension and a symptomatic
decline in the course of the CTEPH and is related to the
development of persistent pulmonary hypertension after
a successful PEA.1,22 A reliable preoperative diagnostic
tool for the involvement of distal arteriopathy has not
been established2,20,22; however, patients who have a PVR
that is disproportionately high with respect to the degree
of proximal obstructions seen on pulmonary angiography
are likely to have significant distal arteriopathy.1,2,4 These
patients have an elevated risk of persistent pulmonary
hypertension and therefore may be selected for PEA only
if a 50% reduction in PVR is predicted.1rdiovascular Surgery c Volume 144, Number 2 325
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DIn conclusion, in our experience PEA provided immedi-
ate and substantial improvements in pulmonary hemody-
namics and had sustained favorable effects on long-term
survival. High PVR was a significant independent risk fac-
tor for in-hospital death. Persistence and worsening of pul-
monary hypertension were associated with late death or
impairment of functional class, and postoperative mPAP
was shown as a risk factor for late adverse events, with an
mPAP value of at least 34 mm Hg being identified as the
cutoff value for the prediction of such late adverse events.
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